What is RECODE?
Over the years, Alzheimer’s drug trials have failed to produce an effective medicine for the disease, leading to the belief that nothing can be done. Today, there is published research documenting it is possible to halt, prevent, and even reverse Alzheimer’s symptoms. See published research here: Reversal of Cognitive Decline: A Novel Therapeutic Program, Reversal of Cognitive Decline in Alzheimer’s Disease.
Dr. Dale Bredesen, MD outlined the therapeutic program in his first NYTimes bestseller, The End of Alzheimer’s. The program has shown how to effectively “turn off” Alzheimer’s; some patients even reversed previous cognitive loss with documented return to normal brain function.
Importantly, the early successes in clinical research demonstrated that Alzheimer’s disease and cognitive decline were not a disease with a single causal factor (i.e., you get Alzheimer’s because you have the ApoE4 gene). Rather, cognitive decline appears to be more like heart disease or cancer—with many triggers occurring throughout the lifetime, culminating with a disease-challenged brain.
Cognitive decline often starts as early as 20-30 years; women are more likely than men to be diagnosed. Risk is only determined in-part by genetics; lifestyle, daily habits and patterns of activity, eating, sleep and brain stimulation appear to play a significant role in the development—and in the reversal—–of cognitive decline.
The ReCODE program is offered by an organization formed by Dr. Bredesen and a team of experts in delivering health programs. The group is called AHNP (click here to learn more) to support and guide individuals who wish to better understand the contributing factors to the development and accumulation of amyloid protein and associated cognitive decline in the brain, and what to do about it.
The program addresses Alzheimer’s Disease and cognitive decline from a multi-factorial perspective as the decline of health and function in the brain follow a similar trajectory to other chronic disease such as cancer and cardiovascular disease. meaning, it tracks and attempts to optimize a variety of biomarkers and behaviors. Extensive lab testing is required in this program to detail which risk factors are present. ReCODE participants usually work with a licensed practitioner (who is certified in the Bredesen Protocol to address the medical and therapeutic concerns, with periodic retesting and re-assessment) and a health coach (to assist with sorting out the top actions and how to implement them).